PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers.

Abstract RNA editing is a widespread post-transcriptional mechanism that confers specific and reproducible nucleotide changes in selected RNA transcripts and plays a critical role in many human cancers. However, little is known about how RNA editing operates in non-small-cell lung cancers. Here, we measured the sequence and expression level of genes of antizyme inhibitor 1 and adenosine deaminase acting on RNA family in 30 non-small-cell lung cancer patient samples and 13 cell lines and revealed RNA editing S367G in antizyme inhibitor 1 is a high-frequent molecular events. We determined overexpression of antizyme inhibitor 1 with RNA editing, implying the oncogenic function of this alteration. We also detected the association of adenosine deaminase acting on RNA overexpression with RNA editing occurred in antizyme inhibitor 1. Furthermore, the RNA editing could cause a cytoplasmic-to-nuclear translocation of antizyme inhibitor 1 protein and conferred the malignant phenotype of non-small-cell lung cancer cells. The in vivo experiment confirmed that this RNA editing confers higher capacity of tumor migration as well. In conclusion, antizyme inhibitor 1 RNA editing and its involvement in tumorigenesis of non-small-cell lung cancer pave a new way for potential clinical management of non-small-cell lung cancer.
PMID
Related Publications

RNA editome imbalance in hepatocellular carcinoma.

Increased HAGLR expression promotes non-small cell lung cancer proliferation and invasion via enhanced de novo lipogenesis.

Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Antizyme inhibitor 1: a potential carcinogenic molecule.

Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Authors

Mayor MeshTerms
Keywords

Non-small-cell lung cancer

RNA editing

adenosine deaminase acting on RNA

antizyme inhibitor 1

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28849733
OWN - NLM
STAT- MEDLINE
DA  - 20170829
DCOM- 20170908
LR  - 20170908
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 8
DP  - 2017 Aug
TI  - RNA editing of AZIN1 induces the malignant progression of non-small-cell lung
      cancers.
PG  - 1010428317700001
LID - 10.1177/1010428317700001 [doi]
AB  - RNA editing is a widespread post-transcriptional mechanism that confers specific 
      and reproducible nucleotide changes in selected RNA transcripts and plays a
      critical role in many human cancers. However, little is known about how RNA
      editing operates in non-small-cell lung cancers. Here, we measured the sequence
      and expression level of genes of antizyme inhibitor 1 and adenosine deaminase
      acting on RNA family in 30 non-small-cell lung cancer patient samples and 13 cell
      lines and revealed RNA editing S367G in antizyme inhibitor 1 is a high-frequent
      molecular events. We determined overexpression of antizyme inhibitor 1 with RNA
      editing, implying the oncogenic function of this alteration. We also detected the
      association of adenosine deaminase acting on RNA overexpression with RNA editing 
      occurred in antizyme inhibitor 1. Furthermore, the RNA editing could cause a
      cytoplasmic-to-nuclear translocation of antizyme inhibitor 1 protein and
      conferred the malignant phenotype of non-small-cell lung cancer cells. The in
      vivo experiment confirmed that this RNA editing confers higher capacity of tumor 
      migration as well. In conclusion, antizyme inhibitor 1 RNA editing and its
      involvement in tumorigenesis of non-small-cell lung cancer pave a new way for
      potential clinical management of non-small-cell lung cancer.
FAU - Hu, Xueda
AU  - Hu X
AD  - 1 Biodynamic Optical Imaging Center (BIOPIC), College of Life Sciences, Peking
      University, Beijing, P.R. China.
FAU - Chen, Jingyi
AU  - Chen J
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Shi, Xiaoshun
AU  - Shi X
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Feng, Fenglan
AU  - Feng F
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Lau, King Wai
AU  - Lau KW
AD  - 3 Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - Chen, Yaoqi
AU  - Chen Y
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Chen, Yusong
AU  - Chen Y
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Jiang, Long
AU  - Jiang L
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Cui, Fei
AU  - Cui F
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Zhang, Yalei
AU  - Zhang Y
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Xu, Xin
AU  - Xu X
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
FAU - Li, Jin
AU  - Li J
AD  - 2 State Key Laboratory of Respiratory Disease, National Clinical Research Center 
      for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (AZIN1 protein, human)
RN  - 0 (Carrier Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinogenesis/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/pathology
MH  - Carrier Proteins/*genetics
MH  - Cell Proliferation/genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - RNA Editing/genetics
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Non-small-cell lung cancer
OT  - RNA editing
OT  - adenosine deaminase acting on RNA
OT  - antizyme inhibitor 1
EDAT- 2017/08/30 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/08/30 06:00
AID - 10.1177/1010428317700001 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Aug;39(8):1010428317700001. doi: 10.1177/1010428317700001.